Agonists of the 5-HT1A receptor were the first drugs used for SCA3 treatment and have shown promising results in some smaller-scale trials; however, there have been few recent studies on their efficacy. This evidence concerns the gene HTR1A and Spinocerebellar ataxia type 3.